LeMaitre Vascular, Inc. (NASDAQ:LMAT) Director David B. Roberts Sells 3,063 Shares

LeMaitre Vascular, Inc. (NASDAQ:LMAT) Director David B. Roberts sold 3,063 shares of LeMaitre Vascular stock in a transaction dated Tuesday, August 13th. The shares were sold at an average price of $82.07, for a total transaction of $251,380.41. Following the sale, the director now owns 14,114 shares of the company’s stock, valued at $1,158,335.98. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

LeMaitre Vascular Stock Up 1.9 %

NASDAQ LMAT traded up $1.54 on Thursday, hitting $83.59. 92,276 shares of the stock were exchanged, compared to its average volume of 128,873. LeMaitre Vascular, Inc. has a fifty-two week low of $44.27 and a fifty-two week high of $91.76. The company has a market cap of $1.88 billion, a PE ratio of 54.34, a PEG ratio of 2.63 and a beta of 0.89. The company has a 50-day moving average price of $83.17 and a 200-day moving average price of $73.15.

LeMaitre Vascular (NASDAQ:LMAT) last posted its quarterly earnings results on Thursday, August 1st. The medical instruments supplier reported $0.52 EPS for the quarter, topping the consensus estimate of $0.47 by $0.05. LeMaitre Vascular had a net margin of 18.33% and a return on equity of 12.63%. The company had revenue of $55.85 million during the quarter, compared to analysts’ expectations of $54.98 million. During the same quarter in the previous year, the business posted $0.37 EPS. The firm’s revenue was up 11.4% on a year-over-year basis. As a group, equities research analysts predict that LeMaitre Vascular, Inc. will post 1.77 EPS for the current fiscal year.

LeMaitre Vascular Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, August 29th. Shareholders of record on Thursday, August 15th will be issued a dividend of $0.16 per share. This represents a $0.64 annualized dividend and a yield of 0.77%. The ex-dividend date of this dividend is Thursday, August 15th. LeMaitre Vascular’s dividend payout ratio (DPR) is presently 42.38%.

Analyst Ratings Changes

A number of equities research analysts have weighed in on the stock. Stifel Nicolaus upgraded shares of LeMaitre Vascular from a “hold” rating to a “buy” rating and lifted their price target for the company from $59.00 to $75.00 in a research report on Friday, April 26th. JMP Securities lifted their price objective on shares of LeMaitre Vascular from $72.00 to $77.00 and gave the company a “market outperform” rating in a report on Friday, May 3rd. Lake Street Capital started coverage on shares of LeMaitre Vascular in a report on Friday, August 2nd. They issued a “buy” rating and a $105.00 price objective for the company. Roth Capital upgraded shares of LeMaitre Vascular to a “strong-buy” rating in a report on Friday, May 31st. Finally, StockNews.com upgraded shares of LeMaitre Vascular from a “hold” rating to a “buy” rating in a report on Monday. One investment analyst has rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $86.50.

Institutional Trading of LeMaitre Vascular

Institutional investors have recently modified their holdings of the stock. CANADA LIFE ASSURANCE Co raised its stake in LeMaitre Vascular by 44.7% during the 1st quarter. CANADA LIFE ASSURANCE Co now owns 22,252 shares of the medical instruments supplier’s stock worth $1,472,000 after acquiring an additional 6,875 shares in the last quarter. Quantbot Technologies LP boosted its position in shares of LeMaitre Vascular by 1,001.4% in the 1st quarter. Quantbot Technologies LP now owns 7,335 shares of the medical instruments supplier’s stock valued at $487,000 after purchasing an additional 6,669 shares during the period. Ranger Investment Management L.P. boosted its position in shares of LeMaitre Vascular by 1.5% in the 4th quarter. Ranger Investment Management L.P. now owns 912,503 shares of the medical instruments supplier’s stock valued at $51,794,000 after purchasing an additional 13,681 shares during the period. Congress Asset Management Co. MA boosted its position in shares of LeMaitre Vascular by 12.0% in the 1st quarter. Congress Asset Management Co. MA now owns 666,083 shares of the medical instruments supplier’s stock valued at $44,201,000 after purchasing an additional 71,411 shares during the period. Finally, Vanguard Group Inc. boosted its position in shares of LeMaitre Vascular by 2.5% in the 4th quarter. Vanguard Group Inc. now owns 1,548,870 shares of the medical instruments supplier’s stock valued at $87,914,000 after purchasing an additional 38,303 shares during the period. Hedge funds and other institutional investors own 84.64% of the company’s stock.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.